Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Status:
Not yet recruiting
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
This research study is studying a positron emission tomography (PET) agent called
18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of
advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA)
expression or has neuroendocrine features.
The name of the study interventions are:
- 18F-fluciclovine-PET/CT scan
- Two research blood collections